Law firm Kirby McInerney LLP is investigating Option Care Health for potential securities law violations following a significant stock price decline. The company issued optimistic guidance in February 2026 but missed Q1 earnings expectations in April, causing shares to drop 24%. The firm is seeking investors who purchased OPCH securities to discuss potential claims.

Option Care Health (OPCH) shares fell approximately 26-30% after the company reported a Q1 2026 revenue miss and slashed full-year 2026 guidance by $125-225 million, down from $5.8-6.0 billion to $5.675-5.775 billion. The significant guidance cut came just two months after management reaffirmed the original guidance on the Q4 2025 earnings call. Levi & Korsinsky has initiated a securities fraud investigation examining whether the company made materially false or misleading statements regarding patient census changes and Stelara patient conversions.

Johnson Fistel, PLLP announced investigations into GE HealthCare Technologies, Option Care Health, and Rocky Brands on behalf of investors who suffered losses. GE HealthCare disclosed significantly reduced earnings guidance and a $250 million increase in expected input costs due to inflation, leading to a sharp stock price decline.

Option Care Health's stock fell over 30% on April 30, 2026, after the company reported weaker-than-expected first quarter results and cut full year revenue guidance due to a larger than anticipated patient census reset in its chronic inflammatory disease portfolio. Block & Leviton is investigating potential securities law violations and encouraging affected investors to contact them.

Option Care Health (OPCH) stock surged 8% on Tuesday following the announcement of preliminary Q4 2025 financial results. The company reported net sales of $1.46-$1.47 billion (up from $1.35 billion year-over-year) and non-GAAP net income of $73.8-$79 million ($0.46-$0.49 per share). Additionally, the company doubled its share repurchase authorization to $1 billion, demonstrating confidence in its business outlook.

Option Care Health, the largest independent home and alternate site infusion services provider, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026.

Option Care Health reported Q2 2025 financial results with net revenue of $1.42 billion, up 15.4% year-over-year. The company showed resilience in a dynamic marketplace, with adjusted diluted earnings per share of $0.41, up 10.8% from the previous year.

Option Care Health, the largest independent provider of home and alternate site infusion services, reported strong financial results for the fourth quarter and full year 2024, with revenue growth and improved profitability. The company provided guidance for 2025, expecting continued growth and profitability.

AnewHealth, a pharmacy care management provider, has appointed Roman Fry as Chief Growth Officer and Joy Holman as Executive Vice President of Strategic Partnerships. These new hires will help the company expand its reach and reinvent pharmacy care for people with complex, chronic medical needs.

JMP Securities initiated coverage on Option Care Health (OPCH) with a Market Outperform rating and a price target of $36, citing the company's extensive national presence, comprehensive range of therapies, and robust commercial infrastructure as key factors for its positive outlook.

Option Care Health, the largest independent provider of home and alternate site infusion services, will release its Q2 2024 results on July 31, 2024 and host a conference call to discuss the results.

J.Jill, Option Care Health and Amphenol have been highlighted in this Screen of The Week article.